摘要
目的:研究首发精神分裂症患者记忆损害特点及其治疗。方法:30例符合ICD-10精神分裂症诊断标准的首发患者人组,用氯丙嗪治疗(417.5±60.95)mg/d8周前后分别用Wechsler记忆量表(WMS)测定患者的记忆功能、阳性及阴性症状量表(PANSS)及治疗中需处理的不良反应症状量表(TESS),评价患者精神症状及不良反应的严重程度。结果:经配对t检验,精神分裂症患者治疗前后的记忆商数(MQ)及其部分分测验(视觉再认测验、联想学习测验、触觉测验及理解记忆测验)具有显著差异(P<0.05)。治疗前后MQ的差值与PANSS总分差值及阳性总分差值具有相关性(r分别为0.423及0.534)。结论:(1)首发精神分裂症患者在发病初期就存在记忆损害。(2)氯丙嗪对精神分裂症的记忆损害具有一定改善作用,短时记忆某些成份的改善与精神症状(阳性症状)的好转具有相关性。
Objective： To explore the characteristics and the treatment of memory impairments in first-episode schizophrenic patients. Methods： 30 first-episode drug-naive schizophrenic patients diagnosed with ICD-10 were recruited in the study and received the treatment of chlorpromazine [（417. 5±60. 95）mg/d] for 8 weeks. The total score and subscores on Wechsler memory scale（WMS） were obtained for all the patients pre- and post-treatments,and the patients were also assessed by the Positive and Negative Syndrome Scale（PANSS） and Treatment Emergent Symptorrks Scale（TESS）. Results： With paired-samples t test, the differences of The Memory Quotient（MQ） and its part iterns between pre-and post-treatment were significant（P〈0. 05） ,and the difference of MQ pre- and post-treatment was significantly correlated with that of total score and positive score of PANSS（r = 0. 423 or 0. 534）. Conclusion： （1） This finding supports that the memory impairment exists in the early stage of schizophrenia. （2）Chlorpromazine can improve the memory impairment of schizophrenia,and the efficacy of typical antipsychotics （chlorpromazine） may be related to positive symptoms.
出处
《中国临床医学》
北大核心
2005年第4期715-716,共2页
Chinese Journal of Clinical Medicine
关键词
精神分裂症
记忆损害
氯丙嗪
Schizophrenia
Memory impairments
Chlorpromazine
